

**MEDICAMEN LIFE SCIENCES PVT. LTD.**

CIN NO. U24290DL2022PTC403121, MSME NO. UDYAM-DL-08-0035438  
 Regd. Office: 1506, CHIRANJIV TOWER, 43, NEHRU PLACE, NEW DELHI-110019 (INDIA),  
 Corporate office: 1412 A, CHIRANJIV TOWER, 43, NEHRU PLACE, NEW DELHI-110019 (INDIA)  
**BALANCE SHEET AS AT 31 MARCH, 2024**

(All amounts in Lacs of Rupees. Unless otherwise stated)

PARTICULARS	NOTE NO.	As at 31.03.2024	As at 31.03.2023
<b>I. ASSETS</b>			
<b>1. Non-current assets</b>			
(a) Property Plant & Equipment	3	74.57	29.28
(b) Capital work-in-progress	-	-	-
(c) Financial Assets	-	-	-
(i) Investments	-	-	-
(ii) Trade Receivables	-	-	-
(iii) Loans	-	-	-
(d) Deferred Tax Assets (net)	-	-	-
(e) Other non-current assets	4	8.96	9.35
<b>Total non-current assets</b>		<b>83.53</b>	<b>38.63</b>
<b>2. Current assets</b>			
(a) Inventories	5	5.00	-
(b) Financial Assets	-	-	-
(i) Investments	-	-	-
(ii) Trade Receivables	6	649.19	305.06
(iii) Cash and cash equivalents	7	15.07	33.40
(c) Current Tax Assets (Net)	-	-	-
(d) Other Current Assets	8	6.18	4.23
<b>Total current-assets</b>		<b>675.44</b>	<b>342.69</b>
<b>TOTAL ASSETS</b>		<b>758.97</b>	<b>381.32</b>
<b>II. EQUITY AND LIABILITIES</b>			
<b>1. Equity</b>			
(a) Equity Share Capital	9	913.50	201.00
(b) Other Equity	10	-411.11	118.56
<b>Total Equity</b>		<b>502.39</b>	<b>319.56</b>
<b>Liabilities</b>			
<b>2. Non-current liabilities</b>			
(a) Financial Liabilities			
(i) Borrowings	11	30.48	-
(ii) Trade payables	-	-	-
(iii) Other financial liabilities (other than those specified in item	-	-	-
(b) Provisions	-	-	-
(c) Deferred Tax Liabilities (net)	12	0.60	1.43
(d) Other non-current liabilities	-	-	-
<b>Total non-current liabilities</b>		<b>31.08</b>	<b>1.43</b>
<b>3. Current Liabilities</b>			
(a) Short-term borrowings	-	-	-
Financial Liabilities			
(i) Borrowings	13	92.60	-
(ii) Trade payables	14	82.70	43.19
(iii) Other financial liabilities (other than those specified in item (c)	-	-	-
(b) Other Current liabilities	15	50.20	17.14
(c) Provisions	-	-	-
(d) Current tax liabilities (Net)	-	-	-
<b>Total current liabilities</b>		<b>225.50</b>	<b>60.33</b>
<b>TOTAL EQUITY &amp; LIABILITIES</b>		<b>758.97</b>	<b>381.32</b>

Summary of Significant Accounting Policies


1 & 2

As per our report of even date attached for Rai Qimat & Associates Chartered Accountants

  
 CA Qimat Rai Garg  
 Partner  
 M.No.080857  
 (Firm Reg. No.013152C)  
 Place : Gurgaon  
 Dated : 29.05.2024

  
 Kamal Kishore  
 Pahwa  
 Director  
 DIN : 09670162

for and on behalf of the Board of Directors  
 Medicamen Life Sciences Pvt. Ltd.

  
 Ashwani Kumar  
 Sharma  
 Director  
 DIN: 00325634

  
 Rahul Bishnoi  
 Director  
 DIN: 00317960

# MEDICAMEN LIFE SCIENCES PVT.LTD.

CIN NO. U24290DL2022PTC403121, MSME NO. UDYAM-DL-08-0035438

Regd. Office: 1506, CHIRANJIV TOWER, 43, NEHRU PLACE, NEW DELHI-110019 (INDIA),  
Corporate office: 1412 A, CHIRANJIV TOWER, 43, NEHRU PLACE, NEW DELHI-110019 (INDIA)

## Statement of Profit and Loss for the period 01.04.2023 to 31.03.2024

(All amounts in Lakh of Rupees. Unless otherwise stated)

Particulars	Note No.	For the year ended 31st March, 2024	For the year ended 31st March, 2023
<b>I. REVENUE FROM OPERATIONS</b>			
Sale of Goods/Services	16	692.00	298.34
II. Other income	17	1.01	-
<b>III. Total revenue (1+2)</b>		<b>693.01</b>	<b>298.34</b>
<b>IV. Expenses</b>			
(a) Purchase of Goods	18	126.57	58.87
(b) Stock Increase/Decreased	19	-4.90	-
(c) Employee benefits expense	20	794.74	189.97
(d) Finance Cost	21	2.01	0.01
(d) Depreciation and amortisation expense	3	8.48	1.30
(e) Other expenses	22	148.61	76.20
<b>Total expenses</b>		<b>1,075.51</b>	<b>326.35</b>
<b>V. Profit / (Loss) before exceptional and extraordinary items and tax (3 - 4)</b>		<b>-382.50</b>	<b>-28.01</b>
VI. Exceptional items		-	-
<b>VII. Profit / (Loss) before tax (V - VI)</b>		<b>-382.50</b>	<b>-28.01</b>
<b>VIII. Tax expense:</b>			
(a) Current Tax expenses relating to current year		-	-
(c) Deffered Tax	12	-0.83	1.43
<b>Total Tax Expenses</b>		<b>-0.83</b>	<b>1.43</b>
<b>IX. Profit / (Loss) from continuing operations (9 ±10)</b>		<b>-381.67</b>	<b>-29.44</b>
X. Earnings per equity share:- Basic & Diluted		-4.18	-1.46
XI. Weighted average number of equity Shares			

See accompanying notes forming part of the financial statements

As per our report of even date attached

for Rai Qimat & Associates

Chartered Accountants

CA Qimat Rai Garg

Partner

M.No.080857

(Firm Reg. No.013152C)



for and on behalf of the Board of Directors

Medicamen Life Sciences Pvt. Ltd.

Kamal Kishore

Pahwa

Director

DIN: 09670162

Ashwani Kumar

Sharma

Director

DIN: 00317960

Rahul Bishnoi

Director

DIN : 00317960

Place : Gurgaon

Dated : 29.05.2024

**MEDICAMEN LIFE SCIENCES PVT. LTD.**  
**CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2024**

(All amounts in Lakh of Rupees. Unless otherwise stated)

PARTICULARS	2023-24	2022-23
<b>A. Cash flow from Operating Activities</b>		
Net Profit/(Loss) after tax from continuing operations	-381.67	-29.44
<b>Non-cash adjustment to reconcile profit before tax to net cash flows</b>		
Provision for Taxation	-	-
Adjustments for Deferred Tax	-0.83	1.42
Financial Charges	2.01	-
Depreciation	8.48	1.31
Interest Income	-	-
<b>Operating Profit before Working Capital Changes</b>	<b>-372.01</b>	<b>-26.71</b>
<b>Movements in working capital</b>		
Increase/(decrease) trade payables	39.51	43.19
Increase/(decrease) in long term provisions	-	-
Increase/(decrease) in short term provisions	-	-
Increase/(decrease) in other current liabilities	33.06	17.14
Decrease/(Increase) in trade receivables	-344.13	-305.07
Decrease/(Increase) in inventories	-5.00	-
Decrease/(Increase) in long term loans and advances	-	-
Decrease/(Increase) in short term loans and advances	-	-
Decrease/(Increase) in other current assets	-1.95	-4.22
Decrease/(Increase) in other non current assets	0.39	-9.35
Direct taxes paid	-	-
<b>Net Cash Flow from Operating Activities (A)</b>	<b>-650.13</b>	<b>-285.02</b>
<b>B. Cash Flow from Investing Activities</b>		
Addition to Fixed Assets	-53.77	-30.58
Purchase of non-current investments	-	-
Interest Received	-	-
<b>Net Cash Flow from Investing Activities (B)</b>	<b>-53.77</b>	<b>-30.58</b>
<b>C. Cash Flow from Financing Activities</b>		
Proceeds from issuance of share capital	564.50	349.00
Net proceeds of long term borrowings	30.48	-
Net proceeds of short term borrowings	92.60	-
Net proceeds of Investment	-	-
Financial Charges	-2.01	-
<b>Net Cash Flow from Financing Activities (C)</b>	<b>685.57</b>	<b>349.00</b>
<b>NET INCREASE/(DECREASE) IN CASH &amp; CASH EQUIVALENTS (A+B+C)</b>	<b>-18.33</b>	<b>33.40</b>
Cash & Cash Equivalents at the beginning of the year	33.40	-
Cash & Cash Equivalents at the end of the year	15.07	33.40

As per our report of even date attached

for Rai Qimat & Associates

Chartered Accountants

CA Qimat Rai Garg

Partner

M.No.080857

(Firm Reg. No.013152C)

Place : Gurgaon

Dated : 29.05.2024



for and on behalf of the Board of Directors

Medicamen Life Sciences Pvt. Ltd.

Kamal Kishore

Pahwa

Director

DIN: 09670162

Ashwani Kumar

Sharma

Director

DIN: 00317960

Rahul Bishnoi

Director

DIN: 00325634

**MEDICAMEN LIFE SCIENCES PVT. LTD.**

Notes forming part of the financial statements

(All amounts in Lacs of Rupees. Unless otherwise stated)

**Note 3 Fixed assets**

Sr. No.	Tangible assets	Rate SLM	Gross block				Accumulated depreciation and impairment				Net block	
			Balance as at 1 April, 2023	Additions	Disposals	Balance as at 31 March, 2024	Balance as at 1 April, 2023	Depreciation for the year	Eliminated on disposal of assets	Balance as at 31 March, 2024	Balance as at 31 March, 2024	Balance as at 31 March, 2024
1	Computer	31.67%	4.40	0.41	-	4.81	0.51	1.47	-	1.98	2.83	
2	Furniture & Fixture	9.50%	20.75	-	-	20.75	0.51	1.97	-	2.48	18.27	
3	Office Equipment	19.00%	3.61	5.67	-	9.28	0.16	1.21	-	1.37	7.91	
4	Airconditioners	19.00%	1.71	0.26	-	1.97	0.12	0.35	-	0.47	1.50	
5	Books	9.50%	0.11	-	-	0.11	-	0.01	-	0.01	0.10	
6	Vehicle	11.88%	-	47.43	-	47.43	-	3.47	-	3.47	43.96	
	<b>Total</b>		<b>30.58</b>	<b>53.77</b>	<b>-</b>	<b>84.35</b>	<b>1.30</b>	<b>8.48</b>	<b>-</b>	<b>9.78</b>	<b>74.57</b>	

Sr. No.	Tangible assets	Rate SLM	Gross block				Accumulated depreciation and impairment				Net block	
			Balance as at 1 April, 2022	Additions	Disposals	Balance as at 31 March, 2023	Balance as at 1 April, 2022	Depreciation for the year	Eliminated on disposal of assets	Balance as at 31 March, 2023	Balance as at 31 March, 2023	Balance as at 31 March, 2023
1	Computer	31.67%	-	4.40	-	4.40	-	0.51	-	0.51	3.89	
2	Furniture & Fixture	9.50%	-	20.75	-	20.75	-	0.51	-	0.51	20.24	
3	Office Equipment	19.00%	-	3.61	-	3.61	-	0.16	-	0.16	3.45	
4	Airconditioners	19.00%	-	1.71	-	1.71	-	0.12	-	0.12	1.59	
5	Books	9.50%	-	0.11	-	0.11	-	-	-	-	0.11	
	<b>Total</b>		<b>-</b>	<b>30.58</b>	<b>-</b>	<b>30.58</b>	<b>-</b>	<b>1.30</b>	<b>-</b>	<b>1.30</b>	<b>29.28</b>	

for Rai Qimat & Associates  
Chartered Accountants



*Rai Qimat*

CA Qimat Rai Garg  
Partner

M.No.080857

(Firm Reg. No.013152C)

Place : Gurgaon

Dated : 29.05.2024

For and on behalf of the Board of Directors  
MEDICAMEN LIFE SCIENCES PVT. LTD.

*Ashwani Kumar Sharma*

Ashwani Kumar Sharma  
Director  
DIN : 00325634

*Kamal Kishore Pahwa*

Kamal Kishore Pahwa  
Director  
DIN : 09670162

*Rahul Bishnoi*

Rahul Bishnoi  
Director  
DIN : 00317960

**MEDICAMEN LIFE SCIENCES PVT. LTD.**  
Notes forming part of the financial statements as on 31.03.2024  
(All amounts in Lacs of Rupees. Unless otherwise stated)

Particulars	As at 31st March 2024	As at 31st March 2023
<b>Note 4 Other Non Current Assets (Misc. Exp.)</b>		
Preliminary Expenses	11.20	11.69
Less W/off during the year	2.24	2.34
	<u>8.96</u>	<u>9.35</u>
<b>Note 5 Inventories</b>		
Inventories (at close)	4.90	-
Inventories (at commencement)	-	-
	<u>4.90</u>	<u>-</u>
<b>Note 6 Trade Receivables</b>		
Sundry Debtors	649.19	305.06
	<u>649.19</u>	<u>305.06</u>

**Trade receivable Ageing as at 31st March'2024**

Particulars	Less than 6 Months	6 Months -1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
(i). Undisputed Trade receivables – considered good	610.24	38.96	-	-	-	649.19
(ii) Undisputed Trade Receivables – considered doubtful	-	-	-	-	-	-
(iii) Disputed Trade Receivables considered good	-	-	-	-	-	-
(iv) Disputed Trade Receivables considered doubtful	-	-	-	-	-	-
<b>Total</b>	610.24	38.96	-	-	-	649.19

**Trade receivable Ageing as at 31st March'2023**

Particulars	Less than 6 Months	6 Months -1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
(i). Undisputed Trade receivables – considered good	278.71	26.35	-	-	-	305.06
(ii) Undisputed Trade Receivables – considered doubtful	-	-	-	-	-	-
(iii) Disputed Trade Receivables considered good	-	-	-	-	-	-
(iv) Disputed Trade Receivables considered doubtful	-	-	-	-	-	-
<b>Total</b>	278.71	26.35	-	-	-	305.06

**Note 7 Cash and Cash Equivalents**

Cash in hand	0.08	0.31
Balances with banks	3.34	22.09
Fixed Deposits with bank	11.65	11.00
	<u>15.07</u>	<u>33.40</u>

**Note 8 Other Current Assets**

Tax Deducted at Sources	0.76	0.26
Tax Collect at Sources	0.46	-
Balance with Statutory Authorities (GST Recoverable)	0.51	-
Rent Security	1.72	1.72
Accrued Interest on FDR	0.29	-
Advance To Staff	1.30	1.07
Advance to suppliers	0.14	1.18
Gift Voucher	1.00	-
	<u>6.18</u>	<u>4.23</u>

**Note 9 Capital Account**

**a) Equity Share Capital**

Authorised (1,00,00,000 equity shares of Rs. 10/- each	1,000.00	1,000.00
Issued, subscribed and paid up 40,10,000 equity shares of Rs. 10/- each fully paid)	913.50	201.00
<b>Subscribed and fully paid up</b> (Equity shares of Rs. 10/- each with voting rights )	913.50	201.00
	<u>913.50</u>	<u>201.00</u>



## Particulars

As at  
31st March 2024As at  
31st March 2023b) The reconciliation of the number of shares  
Particulars

Particulars	As at 31st March 2024		As at 31st March 2023	
	Shares In Numbers	Amount	Shares In Numbers	Amount
Number of Shares at the beginning	2010000.00	201.00	-	-
Add: Shares issued during the year	7125000.00	712.50	2010000	201.00
Number of Shares at the End	9135000.00	913.50	2010000	201.00

c) The details of shareholders holding more than 5% shares  
Name of Share Holder

Name of Share Holder	As at 31st March 2024		As at 31st March 2023	
	Shares In Numbers	% Held	Shares In Numbers	% Held
1. Medicamen Biotech Limited (AAACM1217A)	5695100	62.34	1025100	51.00
2. Kamal Kishore Pahwa (AAOPP7107K)	1212450	13.27	492450	24.50
3. Pramod Kumar Sharma (AAQPS9827F)	2227450	24.38	492450	24.50
	9135000	100.00	2010000	100.00

## d) Details of Number of shares held by Promoters

Shares held by promoters at the end of the 2023-24 Name of Promoters	Number of Shares			Percentage of shareholding		
	01.04.23 Opening	2023-24 Addition	31.03.2024 Closing	01.04.23 Opening	31.03.2024 Closing	2023-24 Change
1. Medicamen Biotech Limited (AAACM1217A)	1025100	4670000	5695100	51.00%	62.34%	11.34%
2. Kamal Kishore Pahwa (AAOPP7107K)	492450	720000	1212450	24.50%	13.27%	-11.23%
3. Pramod Kumar Sharma (AAQPS9827F)	492450	1735000	2227450	24.50%	24.38%	-0.12%
<b>Total</b>	<b>2010000</b>	<b>7125000</b>	<b>9135000</b>	<b>100.00%</b>	<b>100.00%</b>	

## Note 10 Other Equity

Opening balance		-29.44	-
Add: Profit / Loss for the year		-381.67	-29.44
Closing balance		-411.11	-29.44
Share application money received		-	148.00
<b>Total</b>		<b>-411.11</b>	<b>118.56</b>

## NOTE 11 LONG TERM BORROWINGS

Car Loan from HDFC Bank		37.86	-
Less: Current Maturity		-7.38	-
		<b>30.48</b>	<b>-</b>

## NOTE 12 Deferred Tax

## Deferred Tax Liability arising on account of:

Opening Deferred Tax Asset/Liability		1.43	-
WDV as per income tax act		71.37	29.28
WDV as per co. act		74.57	23.79
Difference		-3.20	5.49
Current DTL		-0.83	1.43
<b>Closing Deferred Tax Asset/Liability</b>		<b>0.60</b>	<b>1.43</b>

## Note 13 Borrowings

HDFC Bank Cash Credit		92.60	-
		<b>92.60</b>	<b>-</b>

## Note 14 Trade Payables

Sundry Creditors		82.70	43.19
		<b>82.70</b>	<b>43.19</b>

## Trade Payable ageing as at 31 March'2024

Particulars	Outstanding for following periods from due date of payment					
	Less than 6 Month	6 Months - 1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
(i) MSME	-	-	-	-	-	-
(ii) Others	56.33	26.37	-	-	-	82.70
(iii) Disputed dues - MSME	-	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-	-
<b>Total</b>	<b>56.33</b>	<b>26.37</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>82.70</b>

## Trade Payable ageing as at 31 March'2023

Particulars	Outstanding for following periods from due date of payment					
	Less than 6 Month	6 Months - 1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
(i) MSME	-	-	-	-	-	-
(ii) Others	-	43.19	-	-	-	43.19
(iii) Disputed dues - MSME	-	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-	-
<b>Total</b>	<b>-</b>	<b>43.19</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>43.19</b>

Particulars	As at 31st March 2024	As at 31st March 2023
<b>Note 15 Other current liabilities</b>		
Expenses Payable	10.27	9.52
TDS & GST Payable	15.80	4.78
PF & ESIC Payable	5.48	2.84
Audit Fees Payable	0.35	-
Salary Payable	1.64	-
Bonus & Leave Payable	2.45	-
Current Maturity of Long term Debts	7.38	-
Cheque issued but not presented	6.83	-
	<u>50.20</u>	<u>17.14</u>
<b>Note 16 Revenue from operations</b>		
Sale of Goods	692.00	298.34
	<u>692.00</u>	<u>298.34</u>
<b>Note 17 Other Income</b>		
Interest on FDR	1.01	-
	<u>1.01</u>	<u>-</u>
<b>Note 18 Purchase of Goods</b>		
Purchase of Traded Goods	126.57	58.87
	<u>126.57</u>	<u>58.87</u>
<b>Note 19 Stock Increase/Decreased</b>		
Opening Stock	-	-
Purchase during the year	126.57	58.87
Less: Consumption during the year	121.67	58.87
Closing stock	4.90	-
<b>Stock Increase/Decreased</b>	<u>4.90</u>	<u>-</u>
<b>Note 20 Employee benefits expense</b>		
Salary Exp.	505.84	111.37
Directors Remuneration	100.02	29.46
Contribution to ESIC	0.12	0.03
Contribution to PF	27.13	6.79
EPF Admin Charges	1.79	0.39
Leave Encashment	0.26	1.97
Bonus Expenses	0.29	1.82
Staff Welfare	11.46	35.67
Local Conveyance	12.13	2.47
Boarding & Loading Allowance	18.82	-
Conveyance Allowance	93.30	-
Incentive	9.24	-
Staff Training	14.34	-
	<u>794.74</u>	<u>189.97</u>
<b>Note 21 Financial Expenses</b>		
Interest on TDS & GST	-	0.01
Interest on CCL	0.02	-
Interest on Car Loan	1.99	-
	<u>2.01</u>	<u>0.01</u>



	As at 31st March 2024	As at 31st March 2023
<b>Note 22 Other Expenses</b>		
<b>Expenses (Direct)</b>		
Carriage & Freight	0.48	0.23
Product Development	0.72	0.70
Product Registration	1.39	0.50
	<u>2.59</u>	<u>1.43</u>
<b>Expenses (Indirect)</b>		
Bank Charges	0.48	0.01
GST Expenses	0.05	-
Office Expenses	0.68	2.28
Water & Electricity	1.78	0.36
Telephone Expenses	3.26	0.66
Postage & Courier Expenses	4.57	0.19
Audit Fees	0.35	0.35
Business Promotion	75.46	53.22
Printing & Stationery	1.43	4.63
Repair & Main.	0.98	2.28
Vehicle Running & Maint	3.22	-
Tour & Travel	26.37	1.17
Insurance Exp.	8.93	4.16
Festival Celebration	3.86	-
Professional Expenses	0.51	0.04
Rent	6.87	2.86
Rent on Machinery	0.27	0.10
Software & Subscription	4.36	0.09
Board & Secretarial Expenses	0.30	-
Filing Fees	0.05	0.03
Preliminary Expenses w/off	2.24	2.34
	<u>146.02</u>	<u>74.77</u>
	<u>148.61</u>	<u>76.20</u>

for Rai Qimat & Associates  
Chartered Accountants

*Okaidhy*

CA Qimat Rai Garg  
Partner

M.No.080857  
(Firm Reg. No.013152C)  
Place : Gurgaon  
Dated : 29.05.2024



For and on behalf of the Board of Directors  
MEDICAMEN LIFE SCIENCES PVT. LTD.

*Kamal Kishore Pahwa*

Kamal Kishore  
Pahwa

Director  
DIN :  
09670162

*Ashwani Kumar Sharma*

Ashwani Kumar  
Sharma

Director  
DIN : 00325634

*R. Bishnoi*

Rahul Bishnoi

Director  
DIN : 00317960